Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
| ▸ | VEGFA | P15692 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904099 | 0.85 | LMNA (0.39) | TBXA2RTLR8CTSSCTSKCTSB | |
| SCHEMBL22904436 | 0.82 | AR (0.39) | CTSSCTSKAAK1ARSLC6A2 | |
| SCHEMBL22904304 | 0.79 | AR (0.37) | AAK1ARPOLBGAA | |
| SCHEMBL24548383 | 0.74 | CTSK (0.41) | NPSR1CTSSCTSKCTSBAAK1 | |
| SCHEMBL29348331 | 0.72 | CTSS (0.36) | CTSSCTSKCTSBGAA | |
| SCHEMBL22904176 | 0.72 | ALDH1A1 (0.38) | NPSR1MAPTEPAS1GAA | |
| SCHEMBL22904531 | 0.70 | KMT2A (0.42) | TBXA2RNPSR1ARMAPTEPAS1 | |
| SCHEMBL25981486 | 0.70 | POLB (0.49) | TLR8ARHSD11B1MAPTSLC6A2 | |
| SCHEMBL26633408 | 0.70 | CTSS (0.43) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL15268526 | 0.69 | CTSS (0.41) | CTSSCTSKCTSBAAK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CDR2 | TBXA2R 4860/4885TLR8 4212/4885NPSR1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.